The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Novo Nordisk has received its first European approval for an oral version of Wegovy, bringing a pill-based semaglutide option closer to reality for weight loss patients. This is a significant step beyond the current injectable format. Here's what it means for people considering or currently using GLP-1 medications.
UVM Health Network is eliminating GLP-1 weight-loss drug coverage for its employees, leaving many workers scrambling for alternatives. This move reflects a broader national trend of employers pulling back on obesity medication benefits due to high costs. If you're affected, here's what you need to know and what steps to take next.
Novo Nordisk is preparing to launch a lower-cost version of Ozempic in South Africa, signaling a potential shift in how the company prices semaglutide across different markets. For patients in the U.S. and elsewhere who struggle with GLP-1 medication costs, this move raises important questions about global pricing fairness and what alternatives exist today.
Compounding pharmacies continue to supply a significant portion of GLP-1 medications in the U.S., even as brand-name drugs like Ozempic and Wegovy return to shelves. This article breaks down what that market reality means for patients weighing cost, access, and safety when choosing between compounded and brand-name options.
India has approved Wegovy for the treatment of fatty liver disease, marking a significant expansion of semaglutide's approved uses. This follows growing clinical evidence that GLP-1 medications can reduce liver fat and inflammation. Here's what patients need to know.
An Indian pharmaceutical company is preparing to launch a generic version of semaglutide, the active ingredient in Ozempic, in South Africa. This could mark a turning point for GLP-1 access in emerging markets. Here is what patients and providers should understand about what is coming.
Boehringer Ingelheim has moved its investigational triple receptor agonist BI 3034701 into Phase II clinical trials, targeting GLP-1, GIP, and NPY2 receptors simultaneously. This makes it a potential first-in-class treatment that goes beyond current dual-receptor drugs like tirzepatide. Here's what patients should know about this development and what it means for the future of obesity treatment.
Online searches for weight-loss medications have exploded 25-fold since GLP-1 drugs like Ozempic and Wegovy entered the market. This surge reflects real demand, but it also means more confusion and misinformation. Here's how to cut through the noise and find information that actually helps you.
.avif)
